Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
16 mars 2023 07h30 HE
|
Monte Rosa Therapeutics, Inc.
Phase 1/2 clinical trial evaluating MRT-2359 for treatment of MYC-driven solid tumors ongoingDisclosure of initial data from Phase 1 arm of study expected in second half of 2023MRT-2359 received Fast...
Monte Rosa Therapeutics to Present at Upcoming Investor Conferences
03 févr. 2023 07h30 HE
|
Monte Rosa Therapeutics, Inc.
BOSTON, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the...
Monte Rosa Therapeutics Outlines Progress Across Portfolio of Molecular Glue Degraders and Key Anticipated Milestones for 2023
09 janv. 2023 07h30 HE
|
Monte Rosa Therapeutics, Inc.
MRT-2359 received Fast Track designation from the FDA for the treatment of patients with previously treated, metastatic non-small cell lung cancer (NSCLC) with L-MYC or N-MYC expressionDisclosure of...
Monte Rosa Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
04 janv. 2023 07h30 HE
|
Monte Rosa Therapeutics, Inc.
BOSTON, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that...
Monte Rosa Therapeutics Reports Third Quarter 2022 Financial Results and Business Updates
10 nov. 2022 07h30 HE
|
Monte Rosa Therapeutics, Inc.
– Initiated Patient Dosing in Phase 1/2 Clinical Trial Evaluating MRT-2359, a GSPT1-directed Molecular Glue Degrader, for Treatment of MYC-driven Tumors – – Progressed VAV1 Molecular Glue Degrader...
Monte Rosa Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating MRT-2359, a GSPT1-directed Molecular Glue Degrader, for Treatment of MYC-driven Tumors
01 nov. 2022 07h30 HE
|
Monte Rosa Therapeutics, Inc.
BOSTON, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the...
Monte Rosa Therapeutics Announces Participation in Upcoming Investor Conferences
31 oct. 2022 16h30 HE
|
Monte Rosa Therapeutics, Inc.
BOSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader-based medicines, today announced the company...
Monte Rosa Therapeutics to Present at 5th Annual Targeted Protein Degradation Summit and 34th EORTC-NCI-AACR Symposium
20 oct. 2022 16h30 HE
|
Monte Rosa Therapeutics, Inc.
– New and Updated Preclinical Data Highlight Potential of GSPT1-directed Molecular Glue Degrader (MGD) MRT-2359 in the Treatment of MYC-driven Cancers – – Novel and Proprietary AI/Machine Learning...
Monte Rosa Therapeutics Announces FDA Clearance of Investigational New Drug Application for MRT-2359, a GSPT1-directed Molecular Glue Degrader
06 sept. 2022 07h30 HE
|
Monte Rosa Therapeutics, Inc.
BOSTON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that...
Monte Rosa Therapeutics Reports Second Quarter 2022 Financial Results and Business Updates
11 août 2022 07h30 HE
|
Monte Rosa Therapeutics, Inc.
– Submitted Investigational New Drug (IND) Application for MRT-2359, a GSPT1-directed Molecular Glue Degrader for the Treatment of Myc-driven Solid Tumors – – Cash Runway into Late 2024 with $299.5...